The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study)

International Journal of Clinical Practice

Volumn 68, Issue 2, 2014, Pages 203-215

  Hackett, G ^a   Cole, N ^a   Bhartia, M ^a   Kennedy, D ^a   Raju, J ^a   Wilkinson, P ^b   Saghir, A ^c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b Wilkinson Associates Radnet   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIDIABETIC AGENT; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DEFICIENCY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HUMAN; HYPOGONADISM; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84893638940     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12235     Document Type: Article

References (47)

1. Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, der Ronde W,. EAU guidelines on male hypogonadism. http://www.uroweb.org/gls/pdf/16-Male- Hypogonadism-LR%20II.pdf (accessed 07/06/2013).
2. Wang C, Nieschlag E, Swerdloff RS, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in Males; ISA, ISSAM, EAU, EAA, ASA Recommendation. Eur Urol 2009; 55: 121-130.
3. Wylie K, Rees M, Hackett G, et al. Androgens, health and sexuality. Maturitas 2010; 67: 275-89.
4. Zitzmann M, Faber E, Nieschlag E,. Association of specific symptoms and metabolic risk with serum testosterone in order men. J Clin Endocrinol Metab 2006; 91: 4335-43.
5. Wu FW, Tajar A., Beynon JM, et al., for the EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-136.
6. http://Documents/Reports/Diabetes-in-the-UK-2010.pdf (accessed 18/5/2013).
7. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. J Clin Endocrin Metab 2004; 89: 5462-8.
8. Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911-17.
9. Hackett G, Cole N, Deshpande A, Popple M, Kennedy D, Wilkinson P,. Biochemical hypogonadism and type 2 diabetes in primary care. Br J Diab Vasc Dis 2009; 9: 216-2315.
10. Gan E, Pattmann S, Pearce S, Quinton R,. Many men are receiving unnecessary testosterone prescriptions. BMJ 2012; 345: e5469. doi: http://dx.doi.org/10.1136/bmj.e5469 (Published 21 August 2012)
11. Gan E, Pattmann S, Pearce S, Quinton R,. A UK epidemic of testosterone prescribing. Clin Endocrinol 2013. doi: 10.1111/cen.12178.
12. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007; 116; 2694-2701.
13. Hak AE, Witteman JCM, De Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 2002; 87: 3632-9.
14. Shores MM, Matsumoto AM, Sloan KL, et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-65.
15. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Endocrinol Metab 2009; 94: 2482-2488.
16. Maggi M, Laurentini F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6 year mortality in older men in the Chianti area. Arch Int Med 2007; 167: 2249-2254.
17. Hyde Z, Norman P, Flicker L, et al. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health in Men Study. J Clin Endocrin Metab 2012; 1: 179-189.
18. Malkin CJ, Pugh PJ, Morris PD, et al. Serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96: 1821-1825.
19. OhJ Y, Barrett-Connor E, Wedick NM, Wingard DL, Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.
20. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB,. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490-4.
21. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2006; 27: 3452-3458.
22. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4446.
23. Quality Outcome Framework in Diabetes 2012 /13. http://www.nhsemployers. org/Aboutus/Publications/Documents/ (accessed 7/6/13)
24. Home P, Mant J, Diaz J, Turner C, on behalf of the Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008; 336: 1306-1308.
25. Hackett GI, Kirby M, Jackson G, Wylie K,. Evidence based medicine inevitably increases testosterone prescribing. BMJ 2012; 345: e6167.
26. Hackett GI, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P,. Testosterone replacement therapy with long acting testosterone undecanoate improves sexual function and quality of life parameters vs placebo in a population of men with type 2 diabetes. J Sex Med 2013; 10: 1612-1627.
27. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long term treatment for men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429-5434.
28. Heineman LA, Zimmermann T, Vermeulen A, Theil C,. A new Aging Male Symptom rating scale (AMS). Aging Male 1999; 2: 105-114.
29. Zigmond AS, Snaith RP,. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.
30. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A,. The International index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
31. Bondara E, Formenttini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002; 25: 1135-1141.
32. Huhtaniemi I, Tajar A, Lee D, et al. Comparison of serum testosterone and oestradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol 2012; 166: 983-991.
33. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672.
34. Kalinchenko S, Tishova Y, Mskhalaya G, Gooren L, Giltay E, Saad F,. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol 2010; 73: 602-612.
35. Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010; 7: 2572-82.
36. Zitzmann M, Mattern A, Hanisch J, Looren L, Jones TH, Maggi M,. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2012; 10: 579-588.
37. Yassin AA, Saad F, Traish A,. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006; 3: 727-735.
38. Saad F, Aversa A, Isidori A, et al. Onset of effects of testosterone replacement and time span until maximal effect is achieved. Eur J Endocrinol 2011; 165: 675-685.
39. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011; 8: 284-93.
40. Hatzichristou D, Gambia M, Rubio-Aurioles E, Buvat J, brock G, Spera G,. Effects of tadalafil once daily in men with diabetes and erectile dysfunction. Diabet Med 2008; 25: 138-146.
41. Spitzer M, Basaria S, Travison TG, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction. Annals Intern Med 2012; 157: 681-691.
42. Spitzer M, Basaria S, Travison TG, Davda MN, DeRogatis L, Bhasin S,. The effect of testosterone replacement on mood and well being in men with erectile dysfunction. Andrology 2013; 1: 475-482.
43. Kapoor D, Goodwin E, Channer KS, Jones TH,. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
44. Jones TH, Arver S, Behre H, et al. A placebo controlled study on the effects of transdermal testosterone gel in hypogonadal men with type ii diabetes or metabolic syndrome in diabetic control and insulin sensitivity: the TIMES 2 study. Diabetes Care 2011; 34: 828-837.
45. Heufelder AE, Saad F, Bunck MC, Gooren L,. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-733.
46. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle aged and older men: a meta-analysis of randomised placebo controlled trials. J Gerontol 2005; 60: 1451-7.
47. Shabsigh R, Crawford ED, Nehra A, Slawin KM,. Testosterone therapy in hypogonadal men and prostate cancer risk: a systemic review. Int J Impot Res 2009; 21: 9-23.